Form D · Biotechnology

D2G Oncology, Inc.

Mountain View, CA · CIK 0001804747

Offering snapshot reported Apr 27, 2020 · SEC filing

Reported sold
$8.75M
Offering amount: $8.75M
Investors reported
12
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 12, 2020
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$4.37M$8.75MFeb 28, 2020: $6,574,998.00Feb 28, 2020Apr 27, 2020: $8,749,952.00Apr 27, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$6,574,998 → $8,749,952
  • Reported investors9 → 12

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 27, 2020Amendment$8,749,952$2,174,954vs Feb 28, 202012SEC filing
Feb 28, 2020Initial$6,574,998No comparison9SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-361569

Source: Form D, filed Apr 27, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kathy La Porte Director
Kathleen D. La Porte Director
Jonathan Mac Quitty Director, Executive
Dmitri Petrov Director
Monte Winslow Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
297 N. Bernardo Avenue
Mountain View, CA, 94043